ストックスクリーナーアプリを入手
2.68
0.00%
0.00
アフターアワーズ：
2.59
-0.09
-3.36%
Aclaris Therapeutics Inc (ACRS) 最新ニュース
What valuation multiples suggest for Aclaris Therapeutics Inc. stockWeekly Stock Analysis & Long-Term Growth Plans - ulpravda.ru
How Aclaris Therapeutics Inc. stock benefits from strong dollar2025 Breakouts & Breakdowns & AI Powered Trade Plan Recommendations - ulpravda.ru
Is Aclaris Therapeutics Inc. stock affected by interest rate hikesTrade Exit Report & Precise Swing Trade Alerts - ulpravda.ru
Will Aclaris Therapeutics Inc. stock benefit from green energy trendsMarket Performance Recap & Capital Protection Trade Alerts - ulpravda.ru
Market Recap: Can Aclaris Therapeutics Inc. (8AT) stock withstand sector downturnsJuly 2025 Pullbacks & Intraday High Probability Alerts - ulpravda.ru
Why analysts upgrade Aclaris Therapeutics Inc. stockMarket Sentiment Summary & Reliable Momentum Entry Alerts - ulpravda.ru
Aclaris joins Nasdaq biotech index, marking milestone for clinical-stage firm - MSN
Early Trial Data Puts Aclaris’ ATI-052 on Fast Track Toward Bigger Bets - MyChesCo
Why Aclaris Therapeutics Inc. stock could rally in 2025Long-Term Growth Stocks & Superior Growth Trading - ulpravda.ru
Jefferies reiterates Buy rating on Aclaris Therapeutics stock at $7 price target - Investing.com Canada
Aclaris Therapeutics Reports Positive Interim Phase 1a ATI-052 Data, Speeds Up Development Plans - MarketBeat
Aclaris Therapeutics Reports Positive Phase 1a Data For ATI-052 - Nasdaq
Aclaris advances ATI-052 after positive Phase 1a results - TipRanks
Aclaris Therapeutics Announces Positive Interim Results from Phase 1a Trial of ATI-052 - TradingView — Track All Markets
Aclaris reports positive results for anti-inflammatory drug ATI-052 By Investing.com - Investing.com Australia
ACRS: ATI-052 showed best-in-class potential in phase 1a, enabling rapid advancement to phase 1b trials - TradingView — Track All Markets
Aclaris Therapeutics Reports Positive Interim Results for ATI-052 Phase 1a Trials and Outlines Future Development Plans - Quiver Quantitative
New Aclaris antibody shows potential for 3‑month dosing in skin and asthma care - Stock Titan
What analysts say about Aclaris Therapeutics Inc 8AT stockStock Market Trends & Affordable Portfolio Trading - earlytimes.in
Hair Loss Treatment Market Booming with Rapid Growth Through 2032 | Viviscal, Cipla Inc., Aclaris Therapeutics, Inc. - openPR.com
Three Bridge Wealth Advisors LLC Takes Position in Aclaris Therapeutics, Inc. $ACRS - MarketBeat
Why Aclaris Therapeutics Inc. stock remains undervaluedMoving Average Strategies & Exceptional Profit Trading - bollywoodhelpline.com
Aclaris Therapeutics Joins Russell 3000 and Russell 2000 Indexes - MSN
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
What drives Aclaris Therapeutics Inc stock priceEarnings Forecast Updates & Big Profit Low Trading - earlytimes.in
Aclaris Joins Nasdaq Biotech Index, Marking Milestone for Clinical-Stage Firm - MyChesCo
Aclaris Therapeutics, Inc.(NasdaqGS: ACRS) added to NASDAQ Biotechnology Index - marketscreener.com
Gains Report: Is Aclaris Therapeutics Inc stock a good choice for value investorsJuly 2025 Opening Moves & AI Forecast for Swing Trade Picks - moha.gov.vn
Is Aclaris Therapeutics Inc. (8AT) stock good for wealth creationWeekly Trade Recap & Low Drawdown Momentum Trade Ideas - Улправда
Will Aclaris Therapeutics Inc. stock deliver strong dividend growthJuly 2025 Breakouts & Risk Managed Investment Strategies - Улправда
Why Aclaris Therapeutics Inc. stock could see breakout soonJuly 2025 Sector Moves & Safe Capital Growth Tips - Улправда
Why Aclaris Therapeutics Inc. stock is rated strong buyJuly 2025 Gainers & Free Community Consensus Stock Picks - Улправда
How analysts rate Aclaris Therapeutics Inc. stock todayJuly 2025 Catalysts & Safe Capital Preservation Plans - Улправда
Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI) - The Manila Times
Layoff Watch: Why Aclaris Therapeutics Inc. stock could rally in 2025 - Улправда
Aclaris Therapeutics Begins Phase 1a/1b Trial for Investigational Bispecific Antibody ATI-052 - MSN
Aclaris Therapeutics Added to the NASDAQ Biotechnology Index - Investing News Network
Aclaris Therapeutics Included in Nasdaq Biotechnology Index - marketscreener.com
Aclaris Therapeutics Added to Nasdaq Biotechnology Index Effective December 19, 2025 - Quiver Quantitative
Is Aclaris Therapeutics Inc. stock safe for conservative investorsJuly 2025 Weekly Recap & Weekly Top Stock Performers List - Улправда
Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) 25% Share Price Surge Not Quite Adding Up - simplywall.st
Rally Mode: Is Aclaris Therapeutics Inc. (8AT) stock good for wealth creationTrade Risk Assessment & AI Forecasted Entry/Exit Points - Улправда
0.80%
4.56%
大文字化:
|
ボリューム (24 時間):